Concentration and High Avidity of Pneumococcal Antibodies Persist at Least 4 Years after Immunization with Pneumococcal Conjugate Vaccine in Infancy

• DOI: 10.1128/cvi.00039-13
• Publication Date: 2013-05-09T04:01:47Z
• Authors: Nina Ekström; Heidi Åhman; Arto Palmu; Sinikka Grönholm; Terhi Kilpi; Helena Käyhty
• Keywords: Avidity; Pneumococcal Conjugate Vaccine; Pneumococcal polysaccharide vaccine; Pneumococcal infections; Pneumococcal vaccine

ABSTRACT To provide more extensive evidence of long-term effects vaccination on immunity against Streptococcus pneumoniae , a follow-up study the Finnish Otitis Media (FinOM) Vaccine Trial was conducted. One objectives to assess persistence and avidity pneumococcal antibodies 4 years after given in infancy. Children with complete FinOM trial up 24 months age were invited single visit their fifth year life. A blood sample taken from all children for determination anticapsular antibody concentrations vaccine serotypes three serotypes. had been vaccinated at 2, 4, 6, 12 7-valent capsular polysaccharide, CRM197 conjugate (PCV7), or control vaccine. Serum IgG remained significantly higher who received PCV7 than fourth dose. Concentrations frequently carried (6B 19F) declined less those rarely serotype (4), suggesting that natural boosting contributed persistence. Furthermore, recipients. Four doses infancy elicit long-lasting responses high avidity. (This has registered ClinicalTrials.gov under registration no. NCT00378417.)